Peripheral Artery Disease - Pipeline Insight, 2024

This “Peripheral Artery Disease - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Peripheral Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral Artery Disease: Understanding

Peripheral Artery Disease: Overview

Peripheral artery disease (PAD) is a common manifestation of arterial stenosis of the lower and/or upper extremities that reduces arterial flow. It is well known that PAD is associated with elevated morbidity and mortality with cardiovascular (CV) disease. The presence of PAD gives a threefold to sixfold increase in CV mortality compared with gender- and age-matched controls. More than half of PAD patients are reported to have coronary heart disease and cerebrovascular disease because the risk factors for these diseases are common. Gender and coronary heart disease are also additional risk factors for PAD. Because PAD, CV, and cerebrovascular diseases have common risk factors, it is evident that people with PAD are more likely to have these disorders and vice versa. In PAD, symptomatic and asymptomatic patients have different prognosis. In studies to assess the morbidity and mortality of asymptomatic vs. symptomatic PAD patients, it was revealed that the lower ankle-brachial index (ABI) was associated with increased risk in PAD patients compared with those without PAD.

Because of the risk factors associated, all PAD patients should be treated with a secondary prevention strategy that includes risk factor modification. However, fewer PAD patients receive appropriate treatment than those with coronary heart disease, while the strong association between CV morbidity and mortality is recognized. Another important point in the treatment of PAD is the management of intermittent claudication (IC) and critical limb ischemia (CLI), which results in impairment in quality of life (QOL). Although surgical or endovascular interventions are useful, pharmacotherapy is the first-line treatment for patients with the symptoms. CLI is defined as rest/night pain and tissue loss, such as skin ulceration and gangrene, while acute limb ischemia is caused by impaired arterial perfusion to the extremity. In most acute limb ischemia cases, the reason is local arterial thrombosis or embolism; cardiac embolism is the most common cause. An acute arterial perfusion disorder of an extremity may cause life-threatening complications, such as irreversible damage to or loss of the extremity.

Many people with PAD have no symptoms. The most common symptom of lower-extremity PAD is painful muscle cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. However, those who develop a painful ache in their legs when they walk usually disappear after a few minutes of rest. The medical term for this is “intermittent claudication.” The pain can range from mild to severe and usually goes away after a few minutes when you rest your legs. Both legs are often affected simultaneously, although the pain may be worse in one leg.

"Peripheral Artery Disease - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Artery Disease pipeline landscape is provided which includes the disease overview and Peripheral Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Artery Disease.

Peripheral Artery Disease Emerging Drugs Chapters

This segment of the Peripheral Artery Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Artery Disease Emerging Drugs

Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

VM202: Helixmith

VM202 is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith’s non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Peripheral Artery Disease.

Revacept: AdvanceCor

Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

Peripheral Artery Disease: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Artery Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral Artery Disease

There are approx. 18+ key companies which are developing the therapies for Peripheral Artery Disease. The companies which have their Peripheral Artery Disease drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peripheral Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Artery Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Artery Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Artery Disease drugs.

Peripheral Artery Disease Report Insights

• Peripheral Artery Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral Artery Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral Artery Disease drugs?
• How many Peripheral Artery Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Artery Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral Artery Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral Artery Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novo Nordisk
• Helixmith
• AdvanceCor
• Venturis Therapeutics
• VivaCell Biotechnology
• Humacyte
• Bayer
• Vasa Therapeutics

Key Products

• Semaglutide
• VM202
• Revacept
• VT-141
• VCE-004
• Human acellular vessel
• Rivaroxaban
• VS-367

This product will be delivered within 1-3 business days.